WHO ICTRP trial
AMG 386 2nd Ovarian cancer Global Phase 3 clinical trial
JPRN-jRCT2080221277 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221277 |
|---|---|
| Public title | AMG 386 2nd Ovarian cancer Global Phase 3 clinical trial |
| Scientific title | A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers |
| Primary sponsor | Takeda Pharmaceutical Company Limited |
| Secondary sponsors | Amgen Inc., U.S.A. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers |
| Interventions | investigational material(s) Generic name etc : AMG 386 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous control material(s) Generic… |
| Registration date | Oct 21, 2010 |
| Target size | 900 |
| Secondary IDs | JapicCTI-101314 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: